Denali Therapeutics Inc.

Denali Therapeutics Inc. insiders are currently net sellers of DNLI stock, showing bearish sentiment over the past 90 days. Total sales of $462.7M outpace purchases of $5.0M, creating a net outflow of $457.7M. However, 36% of these sales are pre-scheduled 10b5-1 plan transactions.

Denali Therapeutics Inc. has 24 active insiders who have filed SEC Form 4 transactions in the past 90 days. Douglas K. Bratton (Executive) leads with 7 transactions totaling $150.4M. Investors, Inc. Crestline (Executive) follows with 9 transactions worth $133.3M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Denali Therapeutics Inc.'s current score of 1/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Sep 3, 2025, when J. Watts Ryan (Executive) disposed of 50,000 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, DNLI insider trading sentiment is currently bearish with an Alignment Score of 1/100. The negative net flow of $457.7M shows more selling than buying. However, 36% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Denali Therapeutics Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At DNLI, we track all Form 4 filings—currently showing 723 transactions from 24 insiders over 90 days.

A 10b5-1 plan allows Denali Therapeutics Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At DNLI, approximately 36% of recent transactions are 10b5-1 trades. The remaining 64% are discretionary trades, which may carry more informational value.

You can monitor Denali Therapeutics Inc. (DNLI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 24 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Denali Therapeutics Inc.'s current score of 1/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $5.0M in purchases versus $462.7M in sales over 90 days, resulting in a net flow of -$457.7M.

SEC Form 4 filings are mandatory reports that Denali Therapeutics Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At DNLI, the most common type is "S" with 23 occurrences. The most recent Form 4 was filed on Sep 3, 2025 by J. Watts Ryan.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Denali Therapeutics Inc., approximately 36% of recent transactions are executed under 10b5-1 plans, while 64% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.